VA, ASTRO and Washington U. combine forces to drive better care for veterans with cancer

(American Society for Radiation Oncology) The Department of Veterans Affairs today announced a new Radiation Oncology Practice Assessment program to leverage recent advances in information technology to improve radiation therapy cancer care for our nation's Veterans. VA is working with the American Society for Radiation Oncology and Washington University to provide radiation oncologists for the first time with continuous feedback on the progress of cancer therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G Abstract Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223Ra represents the only bone-targeting agent that has ...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
A single session of high-dose-rate brachytherapy safely treated prostate cancer...Read more on AuntMinnie.comRelated Reading: Shorter radiotherapy works for prostate cancer treatment ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer ASTRO releases new prostate radiation therapy guideline SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Conclusions sections. Both authors shared in the final refinement of the manuscript. Funding Salary support for WG by National Science Foundation grant 1624615 is gratefully acknowledged. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We gratefully acknowledge very useful comments from Peter Klein on an earlier version of this manuscript, and from the reviewers of this paper, whose comments have resulted in improvements. An earlier version of this...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Chiu-Min Lin1†, Ching-Fang Yu2,3†, Hsueh-Ya Huang1,4, Fang-Hsin Chen2,3,5, Ji-Hong Hong2,3,5 and Chi-Shiun Chiang1,6,7* 1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan 2Department of Radiation Oncology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan 3Radiation Biology Research Center, Institute for Radiological Research, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan 4Education &Medical Research National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan 5Department of Medical Imaging an...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis study clearly shows that the cell cycle, GNPs, and radiation therapy can be combined to improve outcome of cancer therapy. Using the experimental data, we estimated the predicted improvement for a clinical treatment plan where 30 fractions of 2  Gy radiation dose were given over a period of time. Enhanced uptake and radiation sensitivity of a synchronous tumor cell population would produce a significant improvement in cell killing. For example, synchronizing cells and the addition of LNP–GNPs into tumor cells produced a 1000-fold enhanc ement in cell killing. Because the agents used for cell sync...
Source: Cancer Nanotechnology - Category: Cancer & Oncology Source Type: research
In this report, we are adding an extra finding, in which we show that the levels of circulating NRP-1 were significantly increased in patients who received NAC and had a partial response. Assessing patients who underwent NAC indicated that the levels of NRP-1 measured post-NAC were significantly higher in younger patients and patients with either a low or a medium body mass index (BMI), as well as in patients who remained with larger tumor size and partial response. Previously, we showed that SNAI1 expression in the immune cells collected from the peripheral blood of breast cancer patients was significantly higher in patie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
It was over one hundred years ago that immunotherapy for cancer was first explored by Dr William Coley with the intratumoral injection of bacterial extracts that resulted in tumor regression in select cases. The emergence of surgical procedures, radiation therapy, and chemotherapy eventually became the mainstay of cancer therapies and relegated immune treatments as an unfulfilled pipedream. Nevertheless, it has been apparent that the immune system can play a role in tumor biology as evident by cases of spontaneous tumor regression and increased cancer incidence among immunosuppressed patients.
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Tags: Preface Source Type: research
Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Information Technology | Radiation Therapy | Washington University